T. Rowe Price Associates
AGRX

T. Rowe Price Associates’s Agile Therapeutics AGRX Stock Holding History

T. Rowe Price Associates’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-21
Closed -$21K – 3039
2021
Q4 		$21K Hold
21
– – ﹤0.01% 2959
2021
Q3 		$41K Sell
21
-20
-49% -$45.3K ﹤0.01% 2910
2021
Q2 		$110K Sell
41
-3
-7% -$9.89K ﹤0.01% 2836
2021
Q1 		$182K Buy
44
+21
+91% +$114K ﹤0.01% 2714
2020
Q4 		$131K Buy
23
+16
+229% +$94.2K ﹤0.01% 2607
2020
Q3 		$40K Buy
+7
New +$40.1K ﹤0.01% 2559
2017
Q1 		– Sell
-14
Closed -$158K – 2603
2016
Q4 		$158K Hold
14
– – ﹤0.01% 2420
2016
Q3 		$194K Sell
14
-7
-33% -$99.9K ﹤0.01% 2359
2016
Q2 		$313K Buy
+21
New +$288K ﹤0.01% 2150

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates's AGRX Position: Q1 2022 in Review

T. Rowe Price Associates sold out of Agile Therapeutics (AGRX) in Q1 2022, closing a stake of 21 shares — an estimated $21K sold.

T. Rowe Price Associates first reported a position in AGRX in Q2 2016 and held it in 9 quarters. The position peaked at $313K in Q2 2016. 36 funds tracked by Wall St. Rank hold AGRX as of Q1 2022.

  • T. Rowe Price Associates reported no remaining Agile Therapeutics position as of Q1 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 21 Agile Therapeutics shares in Q1 2022, an estimated $21K.
  • T. Rowe Price Associates first reported a position in Agile Therapeutics in Q2 2016 and held it in 9 quarters.
  • T. Rowe Price Associates's Agile Therapeutics position peaked at $313K in Q2 2016.
  • 36 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2022.

Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.